A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

358

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor
Soft Tissue Sarcoma (STS)
Platinum-resistant Ovarian Cancer (PROC)
Hepatocellular Carcinoma (HCC)
Colorectal Cancer (CRC)
HER2 Negative Breast Cancer
Cutaneous Melanoma
Renal Cell Carcinoma (RCC)

Interventions

DRUG: GI-102 subcutaneous (SC)
DRUG: GI-102
DRUG: doxorubicin
DRUG: paclitaxel
DRUG: bevacizumab
DRUG: eribulin
DRUG: trastuzumab deruxtecan (T-DXd)
DRUG: pembrolizumab
DRUG: GI-102

Sponsor

GI Innovation, Inc.

Collaborators

[object Object]